Finished Product Testing Sample Clauses

The Finished Product Testing clause establishes requirements for inspecting and verifying that completed goods meet specified quality and performance standards before acceptance or delivery. Typically, this clause outlines the procedures for conducting tests, the criteria for passing, and the responsibilities of each party in the testing process. For example, it may require the manufacturer to provide test results or allow the buyer to perform independent inspections. Its core function is to ensure that only products conforming to agreed-upon specifications are accepted, thereby reducing the risk of defects and disputes over product quality.
POPULAR SAMPLE Copied 13 times
Finished Product Testing. 6.8.1 Notwithstanding any other provisions herein, for each Batch of Product manufactured under this Agreement, the Purchaser will arrange for Product sample testing in accordance with the requirements set forth in Exhibit D at the Hong Kong Standards and Testing Center, but the Manufacturer shall select, provide and retain samples of the Products according to the requirements in Exhibit D. 6.8.2 Any Batch that fails to meet the requirements in Exhibit D shall not be shipped to the Purchaser and the Purchaser will have no obligation to purchase such Batch of Product The Purchaser will promptly notify the Manufacturer that the Batch has failed the testing and the Parties will mutually agree whether the Product in the Batch should be reworked and retested or disposed. If the failure is caused by the Manufacturer, the rework or disposal of the Product shall be at the Manufacturer’s cost and expense. If the Manufacturer disposes of the Product, the Manufacturer will certify the disposal to the Purchaser in writing.
View SourceView Similar (2)
Finished Product Testing. ChemDevelopment shall be responsible for testing each batch of the Agreement Product (including any testing requiring to be performed by a third party laboratory) to ensure its compliance with the finished product specifications agreed to by SyntheMed. ChemDevelopment shall provide and/or make available a record of the test results for every batch manufactured and details of all out of specification investigations. SyntheMed will review the documentation and approve the release of each batch of material unless otherwise notified (see section 10).
View Source
Finished Product Testing. Following manufacture of the Product, SP will conduct the finished product tests defined in the following table for conformance to the corresponding specification: ------------------------------------------------------------------------------- * An asterisk indicates confidential material has been omitted from this document and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 1. Appearance White fluffy cake or powder free from visible evidence of contamination ------------------------------------------------------------------- 2. USP Sterility Sterile ------------------------------------------------------------------- 3. Particulate analysis by HIAC Per USP -------------------------------------------------------------------
View Source
Finished Product Testing. (a) You shall establish procedures for final acceptance of Finished Products to assure conformance to the Specifications and these Requirements. (b) You shall complete a Certificate of Analysis (COAs) in accordance with Exhibit E of the Agreement for each Batch. COAs shall be sent electronically to the individuals designated by the Customer for approval prior to release of the Batch for delivery. You shall not release the Batch until you receive the Customer’s approval of the COA. (c) When exceptions to the required process described in paragraph (b) above are deemed necessary, such exceptions must be documented in the form of an exception plan and mutually agreed upon. in advance with Customer. (d) You shall randomly select retain samples of the Finished Product that are representative of each Batch. These samples shall be stored under conditions that will preserve the Finished Product for maintenance of the traceability, integrity and Quality of the samples for at least two times the established shelf life of the Finished Product or one year, whichever is shorter, after delivery. (e) You also shall randomly select samples of the Finished Products that are representative of each Batch and ship them to Customer on the same Business Day as the electronic transfer of the COA The Batch and other relevant Quality and traceability information shall be included on the label of each sample. Each sample shall be packed in a manner that preserves its integrity and quality during transport to the Customer.
View SourceView Similar (2)
Finished Product Testing. 9.1 Millennium and Millennium's Authorized Contractors performing manufacture of Product shall have written procedures in place for sampling and testing each batch of the Product prior to release. The procedures, at a minimum, should include: i. Examination of a representative sample of units at the conclusion of finishing operations for correct labeling. ii. Appropriate laboratory testing for conformance to final specifications, including identity and strength of each active ingredient. iii. Current and approved test methods and acceptance criteria. iv. Sampling plans based on commonly accepted statistical criteria. 9.2 Millennium must notify Schering of any batch of the Product that does not meet its release specifications, and authorization for the release of such batch to Schering must come from Schering.
View Source
Finished Product Testing. STI shall be responsible for testing each batch of the Agreement Product (including any testing requiring to be performed by a third party laboratory) to ensure its compliance with the finished product specifications agreed to by SyntheMed. STI shall provide and/or make available a record of the test results for every batch manufactured and details of all out of specification investigations. SyntheMed will review the documentation and approve the release of each batch of material unless otherwise notified (see section 10).
View Source
Finished Product Testing. Biovectra shall be responsible for testing each batch of the Agreement Product (including any testing requiring to be performed by a third party laboratory) to ensure its compliance with the finished product specifications agreed to by SyntheMed. Biovectra shall provide and/or make available a record of the test results for every batch manufactured and details of all out of specification investigations. SyntheMed will review the documentation and approve the release of each batch of material unless otherwise notified (see section 10).
View Source
Finished Product Testing. (a) Prior to packaging and shipment, Atrix will ensure that all bulk finished Product satisfies all required Specifications. (b) For each lot of product shipped to Geneva a certificate of analysis will be supplied as and if requested by Geneva.
View Source
Finished Product Testing. ScinoPharm will perform finished product testing using the approved analytical methods. Any material supplied by or for Theravance shall be manufactured, held, stored, packaged, and tested in accordance with current Good Manufacturing Practices, Theravance specifications, and applicable laws, rules, and regulations.
View Source

Related to Finished Product Testing

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Product Labeling The labeling of all Licensed Products sold or offered for sale under this Agreement shall expressly state that the Licensed Product is manufactured under a license from the Medicines Patent Pool.